<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906513</url>
  </required_header>
  <id_info>
    <org_study_id>OMK20915</org_study_id>
    <nct_id>NCT03906513</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes</brief_title>
  <official_title>Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single-centre, randomized, pilot study. 30 patients with diabetes who
      previously had received Argon laser photocoagulation will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-centre, randomized, pilot study. 30 patients with diabetes who
      previously had received Argon laser photocoagulation will be enrolled. These patients will
      receive corneal esthesiometry and will be divided in those with esthesiometry &lt; 45 mm [6]
      (clinically detectable corneal neuropathy, CDCN) and not (NCDCN).

      Patients will be randomized to the two treatment arms: 20 patients will be treated with
      active treatment (OMK2) and 10 patients will be treated with placebo (lubricant eye drops)
      given three times daily (8 am, 2 pm, 8 pm) for 18 months. Stratification for (1) CDCN, (2)
      duration of the disease, and (3) insulin-dependent diabetes will be adopted.

      The randomization will be operator-masked.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Actual">January 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the characteristics of the subbasal corneal plexus at confocal</measure>
    <time_frame>Change measure (baseline and month 18)</time_frame>
    <description>changes in the characteristics of the subbasal corneal plexus at confocal microscopy (central + 8 paracentral quadrants)
changes in corneal esthesiometry (Cochet-Bonnet esthesiometer); central and four quadrants changes in the characteristics of the subbasal corneal plexus at confocal microscopy (central + 8 paracentral quadrants)
changes in corneal esthesiometry (Cochet-Bonnet esthesiometer); central and changes in the characteristics of the subbasal corneal plexus at confocal microscopy (central + 8 paracentral quadrants)
changes in corneal esthesiometry (Cochet-Bonnet esthesiometer); central and four quadrants four quadrants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- changes in clinical signs and symptoms of ocular surface damage</measure>
    <time_frame>Change measure (baseline and month 18)</time_frame>
    <description>changes in clinical signs of corneal damage (BUT, Schirmer I, corneal and conjunctival epithelial staining using Oxford and Van Bijelsterveld scales, both ranging between 0 - normal, to 4 - severely affected; a change of 1 or more stage is defined as clinically relevant)
changes in symptoms (OSDI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cornea</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients will be treated with active treatment (OMK2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 patients will be treated with placebo (lubricant eye drops)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMK2</intervention_name>
    <description>OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).</description>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Type 1 or type 2 diabetic patients who received Argon Laser Photocoagulation

        Exclusion Criteria:

          -  Neuropathy of any other cause than diabetes

          -  A history of conditions known to affect corneal sensitivity

          -  Coexisting other corneal diseases

          -  Autoimmune diseases

          -  Sjogren syndrome

          -  History of corneal trauma

          -  Contact lenses users

          -  Patients needing eye surgery or who received eye surgery at least 180 days before
             study beginning.

          -  contraindications to the use of any active substances and/or excipients

          -  pregnant and lactating women

          -  pediatric patients or adolescents under 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Fogagnolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Paolo Fogagnolo</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Cornea</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Neural damage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

